Fiche société
Grifols Therapeutics LLC
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IGIV-CThis is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG). | Myasthénie | Phase 2 | United States, Belgium, Canada, Czechia, Estonia, France, Germany, Hungary, … | À vérifier | |
| IGIV-CThis is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG). | Myasthénie | Phase 2 | United States, Belgium, Canada, Czechia, Estonia, France, Germany, Hungary, Lithuania, Poland | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IGIV-C | Myasthénie | Phase 2 | NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | COMPLETED |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| IGIV-C | Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis. | Neurology | ||
| IGIV-C | Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. | Muscle & nerve |